UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

Carcinoma, tuberculosis, atypical pneumonia - or may be pulmonary tularemia? Two case reports

Pneumologie (Stuttgart, Germany), 2024-03, Vol.78 (3), p.199

2024

Link zum Volltext

Verfügbarkeit prüfen

Zeitmanagement

5, 2023

Link zum Volltext

Verfügbarkeit prüfen

Primary Pulmonary Synovial Sarcoma: A Rare Primary Pulmonary Tumor

Lung, 2014-02, Vol.192 (1), p.211-214

2014

Link zum Volltext

Verfügbarkeit prüfen

A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer

Therapeutic advances in medical oncology, 2021, Vol.13, p.1758835921996506-1758835921996506

2021

Link zum Volltext

Verfügbarkeit prüfen

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2019-12, Vol.20 (12), p.1655-1669

2019

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

The New England journal of medicine, 2017-02, Vol.376 (7), p.629-640

2017

Link zum Volltext

Verfügbarkeit prüfen

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients

Journal of thoracic oncology, 2020-01, Vol.15 (1), p.80-90

2020

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab vs placebo for early-stage non‒small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8520-8520

2023

Link zum Volltext

Verfügbarkeit prüfen

Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry

The European respiratory journal, 2023-02, Vol.61 (2), p.2201336

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1224: Combination of rapamycin and crizotinib induces partial remission of pleural mesothelioma in a patient-derived xenograft model

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1224-1224

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer

Journal of cancer research and clinical oncology, 2018-12, Vol.144 (12), p.2457-2463

2018

Link zum Volltext

Verfügbarkeit prüfen

Experience With Afatinib in Patients With Non‐Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib

The oncologist (Dayton, Ohio), 2014-10, Vol.19 (10), p.1100-1109

2014

Link zum Volltext

Verfügbarkeit prüfen

Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer

Oncology research and treatment, 2019-01, Vol.42 (5), p.243-255

2019

Link zum Volltext

Verfügbarkeit prüfen

Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

JTO clinical and research reports, 2024-04, Vol.5 (4), p.100626-100626, Article 100626

2024

Link zum Volltext

Verfügbarkeit prüfen

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin in advanced non-small cell lung cancer (NSCLC) patient

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8051-8051

2015

Link zum Volltext

Verfügbarkeit prüfen

Late lung metastasis of primary endometrial cancer: Two rare cases of patients with late lung metastasis of primary endometrial cancer 14 and 17 years after initial treatment

Memo - Magazine of European medical oncology, 2012-12, Vol.5 (4), p.262-265

2012

Link zum Volltext

Verfügbarkeit prüfen

Selbstgesteuert digital lernen

Wirtschaft + Weiterbildung, 2018-03 (4), p.24-29

2018

Link zum Volltext

Verfügbarkeit prüfen

Global employment and skill level requirements for ‘Post-Carbon Europe’

Ecological economics, 2024-02, Vol.216, p.108014, Article 108014

2024

Link zum Volltext

Verfügbarkeit prüfen

In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography

Brain (London, England : 1878), 2015-03, Vol.138 (Pt 3), p.549-562

2015

Link zum Volltext

Verfügbarkeit prüfen

Direct modulation of aberrant brain network connectivity through real-time NeuroFeedback

eLife, 2017-09, Vol.6

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(51)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(38)
Life Sciences & Biomedicine
(32)
Humans
(24)
Female
(18)
Male
(18)
Aged
(16)
Middle Aged
(16)
Oncology
(15)
Adult
(14)
Lung Neoplasms - Drug Therapy
(8)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(7)
Hematology
(7)
Lung Neoplasms - Pathology
(7)
Mutation
(7)
Treatment Outcome
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Carcinoma, Non-Small-Cell Lung - Pathology
(6)
Clinical Neurology
(6)
Lung Cancer
(6)
Neurosciences & Neurology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Carcinoma, tuberculosis, atypical pneumonia - or may be pulmonary tularemia? Two case reports

Phase II Trial of a Trimodality Regimen for Stage III Non–Small-Cell Lung Cancer Using Chemotherapy As Induction Treatment With Concurrent Hyperfractionated Chemoradiation With Carboplatin and Paclitaxel Followed by Subsequent Resection: A Single-Center Study

Zeitmanagement

Primary Pulmonary Synovial Sarcoma: A Rare Primary Pulmonary Tumor

A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients

Pembrolizumab vs placebo for early-stage non‒small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study

Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry

Abstract 1224: Combination of rapamycin and crizotinib induces partial remission of pleural mesothelioma in a patient-derived xenograft model

Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer

Experience With Afatinib in Patients With Non‐Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib

Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer

A randomized, controlled, open label phase II study of erlotinib (E) with or without the MET antibody emibetuzumab (Emi) as first-line treatment for EGFR mt non-small cell lung cancer (NSCLC) patients who have disease control after an 8-week lead-in treatment with erlotinib

Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial

Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin in advanced non-small cell lung cancer (NSCLC) patient

Phase III study of surgery (S) versus definitive concurrent chemoradiotherapy boost (def ccCRTx-BOx) in patients (pts) with operable (OP+) stage IIIA(N2)/selected IIIb (sel IIIB) non-small cell lung cancer (NSCLC) following induction (IND) chemotherapy (CTx) and concurrent CRTx (ESPATUE)

Late lung metastasis of primary endometrial cancer: Two rare cases of patients with late lung metastasis of primary endometrial cancer 14 and 17 years after initial treatment

Selbstgesteuert digital lernen

Global employment and skill level requirements for ‘Post-Carbon Europe’

In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography

Direct modulation of aberrant brain network connectivity through real-time NeuroFeedback

Suchergebnisse filtern